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atrial fibrillation in comparison with HD patients (79 vs. 66%, 
p = 0.04).  Conclusion: The majority of nephrologists want 
involvement in thrombolysis decisions relevant to their pa-
tients. Concerns about bleeding risks with thrombolysis are 
high and we identify a vital need to improve access to stroke 
rehabilitation in the UK, especially in HD patients. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 Stroke remains a major cause of death and disability 
with an incidence in dialysis patients 10–15 times higher 
than the general population, and it is associated with a 
worse prognosis  [1, 2] . This predilection to stroke is at-
tributed to a higher prevalence of conventional vascular 
risk factors and dialysis-specific causes: accelerated cal-
cific arteriosclerosis, vascular access and the use of anti-
coagulants to maintain flow in the extracorporeal circuit.
 Acute ischaemic stroke accounts for approximately 
70–80% of strokes in dialysis patients. Urgent recanaliza-
tion can be achieved using mechanical embolectomy or 
systemic thrombolysis  [3] . When delivered within 6 h of 
symptom onset in the general population, alteplase re-
sults in a significant improvement in neurodeficit and 
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 Abstract 
 Background/Aims: Systemic thrombolysis for acute isch-
aemic stroke is the standard of care in the UK. In the absence 
of trial data on the safety and efficacy of this treatment in 
patients with end-stage renal disease, we captured the views 
of UK nephrologists to highlight health care policy and re-
search objectives.  Methods: Consultant nephrologists par-
ticipated in an internet-based questionnaire. Respondents 
were asked about their involvement in thrombolysis deci-
sions, safety concerns in dialysis patients, views on stroke 
rehabilitation and opinions on antiplatelet and warfarin use 
for stroke prevention.  Results: 122/433 (28%) clinicians re-
sponded. 75% wanted involvement in thrombolysis deci-
sions although just 10% gave input in practice. 64% ex-
pressed a high degree of concern ( ≥ 7/10) regarding intracra-
nial bleeding risk in haemodialysis (HD). Overall risks of 
intra- and extracranial bleeding were rated lower in perito-
neal dialysis (PD; p < 0.001). 85% felt the HD schedule im-
pacted negatively on rehabilitation, whereas 63% felt this 
was the case in the context of PD (p = 0.001). More clinicians 
favoured warfarin for stroke prevention in PD patients with 
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functional disability compared to placebo  [4] , with a low 
but appreciable risk of haemorrhagic transformation 
which increases further when given >6 h from symptom 
onset  [5] .
 To date the risks and benefits of stroke thrombolysis 
in dialysis patients remain undefined. Renal impairment 
is not a licensed contra-indication to alteplase with no tri-
als to date exploring the effect of kidney function on out-
come. Uraemia confers a bleeding diathesis which is par-
ticularly marked in patients with end-stage renal disease 
(ESRD)  [6] . This is further accentuated with concomitant 
antiplatelet use, regular exposure to heparins during hae-
modialysis (HD) and the effects of hypertension and hy-
pervolaemia. It can therefore be hypothesised that the 
haemorrhagic risk of thrombolysis may outweigh any 
benefits. This concerned the majority of stroke experts 
polled in the only previous survey conducted on this top-
ic  [7] .
 The opinions and experience of nephrologists or kid-
ney patients have never been solicited to date. Further-
more no study has explored the current clinical practice 
in acute stroke management for patients on peritoneal 
dialysis (PD) as well as those receiving HD. We therefore 
sought to comprehensively ascertain the opinions of ne-
phrologists on acute stroke management and thromboly-
sis in the dialysis cohorts under their care.
 Methods 
 Nephrology services across the UK are delivered by large renal 
units, some with and some without transplantation programmes. 
At the time of this survey, 72 renal units (23 with transplantation) 
covered the population of the UK staffed by approximately 460 
consultant renal physicians. We contacted all consultant nephrol-
ogists within the UK by e-mail to participate anonymously in an 
internet-based survey. A second invitation was sent to clinicians 
who had not responded to the initial e-mail within 2 weeks, and all 
responses were evaluated 1 month after the initial request.
 We aimed to capture opinions on a number of facets of care 
around stroke thrombolysis including the role of nephrologists in 
the decision-making process, areas of concern regarding acute 
stroke care and thrombolysis, modifications to the dialysis pre-
scription and what adjuvant pharmacotherapy clinicians supported 
(for questionnaire structure, see online suppl. material; for all on-
line suppl. material, see www.karger.com/doi/10.1159/000357155).
 In the domains where some responses were incomplete, the 
denominator is given in the text. Descriptive statistics were ex-
pressed as the mean ± standard deviation and the median with 
interquartile range as appropriate. Continuous and categorical 
variables were compared using Student’s t test and the χ 2 or Mann-
Whitney U test, respectively, as appropriate. All analyses were per-
formed using STATA 12.1 (www.stata.com). Statistical signifi-
cance was defined by p < 0.05.
 Results 
 Of the 433 clinicians who were invited, 122 (28%) from 
55 centres responded. 69% of the respondents had >15 
years’ practice at the consultant level ( fig.  1 ) with 97% 
providing inpatient cover. The median size of the dialysis 
programme in each centre was 450 patients (73–1,450) 
with PD patients accounting for 16.0 ± 9.6% of the total 
cohort size on average.
 23% of the respondents had dialysis patients in their 
centres who received stroke thrombolysis. The overall 
centre experience varied from 0 to 10 patients reflecting 
the dialysis programme size ( fig. 2 ). Only 10% were actu-
ally involved in thrombolysis decisions, and yet 75% re-
ported a wish for some involvement in the process, with 
82% wanting contact immediately prior to thrombolysis. 
The reasons cited included concerns about the risks of 
thrombolysis weighed against uncertainties about the 
benefits of this treatment in a particularly comorbid sub-
group.
 Key Concerns about Stroke Thrombolysis in Dialysis 
Patients 
 Concerns regarding the risk of bleeding with throm-
bolytic therapy predominated with a significantly higher 
risk perceived in HD patients as compared to those on PD 
(score of 7/10 vs. 6/10) applicable to intracranial and ex-
tracranial bleeding events ( table 1 ). A high bleeding risk 
with thrombolysis (rated  ≥ 7/10) was attributed to HD pa-
Number of years in consultant post
0–3
7–9
13–15
4–6
10–12
>15
 Fig. 1. Clinical experience of survey respondents. 
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tients by 78/122 (64%) clinicians compared with 60/122 
(49%) for PD patients (p = 0.02).
 Clinicians reported a moderate degree of concern re-
garding the impact of dialysis on cardiovascular stability 
around the time of thrombolysis. There was no signifi-
cant difference according to the dialysis modality used 
( table 1 ). Similarly a moderate degree of concern was ex-
pressed regarding the perceived efficacy of this treatment 
as well as issues relating to drug dosing of dialysis patients 
by stroke teams rather than nephrologists ( table 1 ) with 
no significant differences between HD and PD patients. 
There was however an increased level of concern regard-
ing the logistics of delivering HD compared to PD follow-
ing thrombolysis (p = 0.001).
 On average a moderate degree of concern (6/10) was 
raised regarding the available evidence base supporting 
the use of thrombolytic therapy for acute stroke in dialy-
sis patients which did not vary according to dialysis mo-
dality.
 Modification of the Dialysis Prescription in Acute 
Stroke Patients 
 76% of the clinicians would modify the HD prescrip-
tion including some of the following:
 • Avoiding HD unless imperative for the first 24–48 h 
 • Minimisation/avoidance of heparins 
 • Reduction in dialytic efficiency (lower blood pump 
speeds, reductions in dialyser surface area, shorter di-
alysis times) 
 • Daily dialysis or haemofiltration 
 • Limiting ultrafiltration rates 
 In contrast, 20/108 (19%) clinicians would modify the 
PD prescription. Responses were more general in nature 
incorporating reductions in ultrafiltration volume and 
maintaining haemodynamic stability. A quarter of re-
spondents who provided further detail either deferred 
any changes to their PD colleagues or expressed a lack of 
expertise in this area.
 Impact of Dialysis Therapy on Rehabilitation after 
Acute Stroke 
 The majority of respondents felt that the dialysis 
schedule impacted negatively on rehabilitation. This was 
more marked for HD patients (85%) compared to those 
on PD (64%, p = 0.001).
 The adverse effect of HD on rehabilitation was attrib-
uted to issues such as:
 • Treatment time precluding access to rehabilitative ser-
vices such as physiotherapy 
 • Transport to and from the dialysis unit 
 • Dialysis ‘wash-out’ (i.e. time to recovery) 
 • Dialysis mandating an inpatient stay on a nephrology 
ward as opposed to a dedicated stroke unit 
 • Comorbidities limiting the scope for functional im-
provement 
 Antiplatelet/Anticoagulant Therapies after Stroke 
 Over 75% of clinicians would initiate or augment an-
tiplatelet therapies within 48 h of thrombolysis ( table 2 ). 
More clinicians would use warfarin for stroke prevention 
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 Fig. 2. Experience of stroke thrombolysis in ESRD patients accord-
ing to the size of dialysis programme. 
Table 1.  Extent of clinical concern expressed by nephrologists re-
garding the use of thrombolytic therapy for acute stroke according 
to dialysis modality
Degree of clinical concern p
value
HD P D
Risk of intracerebral bleeding 7 (5 – 8) 6 (5 – 7) 0.01
Risk of extracerebral bleeding 6 (4 – 8) 5 (4 – 7) 0.03
Cardiovascular stability 4 (3 – 5) 4 (2 – 5) 0.21
Efficacy 5 (3 – 6) 5 (4 – 6) 0.91
Evidence base for use 6 (3 – 7) 6 (3 – 7) 0.61
Logistics of dialysis delivery 5 (3 – 6) 3 (2 – 5) 0.001
Drug dosing by stroke teams 5 (3 – 7) 5 (3 – 7) 0.26
Other
 Concern: 1 = negligible, 10 = overwhelming. Median values are 
displayed with the interquartile ranges in parentheses.
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in PD patients with atrial fibrillation than in HD (79 vs. 
66%, p = 0.04). This mainly related to bleeding risks as-
sociated with warfarin, and a number of clinicians fa-
voured risk stratification using clinical scores (e.g. HAS-
BLED, CHA2DS2-VASc) with individualised treatment 
decisions based on comorbidity.
 Concluding Comments 
 Overall 76% of the respondents expressed a wish to 
participate in national studies examining clinical out-
comes following stroke thrombolysis. There was no sug-
gestion of conducting a stroke trial comparing thrombol-
ysis to non-thrombolytic care. A number of respondents 
identified research areas of priority such as trials of war-
farin versus antiplatelet therapy alone for stroke preven-
tion in ESRD patients with atrial fibrillation, and on in-
tracerebral haemorrhage in dialysis patients.
 Discussion 
 Stroke thrombolysis in ESRD is dominated by con-
cerns regarding bleeding risks and subsequent access to 
effective rehabilitation. Concerns regarding bleeding 
resonate with those of stroke physicians and remain an 
enduring treatment dilemma  [7] . Higher bleeding rates 
with declining renal function in primary thrombolysis 
for myocardial infarction have been reported in a Swed-
ish registry study but it is unclear whether this is an ef-
fect of treatment choice or renal dysfunction per se  [8] . 
The absence of trial data on the safety of thrombolysis 
in ESRD was reinforced as a significant issue in our 
study. Previously 78% of stroke experts favoured intra-
arterial approaches rather than systemic thrombolysis in 
HD  [7] .
 We found a moderate degree of concern regarding the 
efficacy of thrombolysis in dialysis patients relating to a 
subjective appraisal of comorbid burden and baseline 
functional level rather than issues with the lytic efficacy 
of alteplase in ESRD. Patients with ESRD form compact 
blood clots in vitro that are more resistant to lysis  [9] , but 
it is unclear whether this results in clinically significant 
effects in stroke thrombolysis. Furthermore dialysis pa-
tients have a high prevalence of clinically silent structural 
brain disease (e.g. infarcts, microbleeds) which may at-
tenuate the thrombolytic benefit  [10–12] , in keeping with 
data suggesting that impaired kidney function is an inde-
pendent risk factor for suboptimal post-thrombolysis 
outcomes  [13–15] .
 Dialysis requires specialist nursing input, dedicated 
equipment and, in the case of in-centre HD, a dedicated 
clinical environment. Stroke thrombolysis is delivered in 
hyperacute stroke units in the UK under the direction of 
specialist teams. As a result acute stroke care and reha-
bilitation can be geographically separate from dialysis fa-
cilities. This dichotomy of care at a critical point in the 
patient pathway was highlighted as a major barrier to re-
habilitation, especially for HD patients who require a 
higher level of technological and nursing support com-
pared to those on PD. To date there are no published 
studies on rehabilitation outcomes following stroke in 
ESRD patients. Minimizing the time to recovery from HD 
therapy may improve engagement with rehabilitation 
services  [16] , and co-ordinating dialysis treatments 
around rehabilitation may represent a simple, high-im-
pact intervention. The integration of care remains chal-
lenging, and to date only 1 renal centre in the UK has a 
stroke unit embedded in its nephrology wards.
 We found a striking disparity in the proportion of cli-
nicians who tailor the dialysis prescription after acute 
stroke according to modality. Published recommenda-
tions for HD patients after acute brain injury derive in 
part from data obtained in traumatic brain injury which 
may not be applicable to stroke  [17] . Similar recommen-
Table 2.  Nephrologist opinion on the timing of initiation or augmentation of antiplatelet therapy after acute 
stroke according to dialysis modality
Dialysis modality  Time from thrombolysis
within 1 2 h 12 – 24 h 24 – 48 h 3 days 4 days 1 week 2 weeks >2 weeks
HD (n = 121) 24 (20) 45 (37) 24 (20) 4 (3) 0 4 (3) 2 (2) 2 (2)
PD (n = 111) 30 (27) 40 (36) 24 (22) 2 (2) 0 5 (5) 3 (3) 1 (1)
 Data are given as number of responses with percentages in parentheses.
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dations in PD are lacking, and there are no studies to date 
examining the acute impact of HD or PD on the brain of 
acute stroke patients.
 Despite appreciating platelet dysfunction in ESRD 
most UK nephrologists initiated or incremented anti-
platelet therapies early after thrombolysis. The role of 
warfarin for stroke thromboprophylaxis in dialysis pa-
tients with atrial fibrillation remains contentious. Obser-
vational data in HD has linked warfarin use with a higher 
stroke risk in some studies  [18] , whereas a recent study 
suggested the opposite  [19] . Nonetheless, warfarin con-
ferred a higher bleeding risk in that series in keeping with 
prior data  [20, 21] . Furthermore data suggests that war-
farin can increase the cardiovascular risk directly by ac-
celerated vascular calcification  [22] .
 Our study constitutes the first appraisal of issues 
around stroke thrombolysis in dialysis reflecting topical 
concerns, therapeutic barriers and practical approaches 
to the management of patients. Our study is limited by a 
relatively low response rate despite parity with survey re-
sponse rates in the literature  [23] . Therefore our data may 
be prone to occult bias. In addition nephrologists with 
longer tenure in post were likely overrepresented in this 
study given that around 36% of the nephrologists in the 
UK have >15 years of consultant experience compared to 
69% in this survey (p < 0.001). As a result, our findings 
could be vulnerable to confounding by deriving from a 
distinct, self-selected group of clinicians who nonetheless 
bring a wealth of clinical experience and are more likely 
to influence other professional opinions. A clustering of 
responses particularly from large urban centres (e.g. Lon-
don and Glasgow) may have influenced our results fur-
ther and curb the generalizability of our findings. Finally 
this study represents an assessment of specialist opinion 
which is not a substitute for clinical trial data.
 There is enduring concern regarding systemic throm-
bolysis in dialysis cohorts that appear prejudiced with re-
spect to their rehabilitation. We believe that large collab-
orative studies are needed to determine the safety of this 
therapy in dialysis patients and the optimal care pathways 
to ensure the best post-stroke outcomes. The efficacy and 
safety of warfarin in stroke thromboprophylaxis remains 
contentious, especially in HD patients, and trials are re-
quired to determine the risks and benefits of this agent in 
ESRD.
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